BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang K, Al-Diffhala S, Centeno BA. Primary Liver Cancers-Part 1: Histopathology, Differential Diagnoses, and Risk Stratification. Cancer Control. 2018;25:1073274817744625. [PMID: 29350068 DOI: 10.1177/1073274817744625] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019;8:E1172. [PMID: 31569444 DOI: 10.3390/cells8101172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
2 Li P, Liu Y, He Q. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation. Drug Des Devel Ther 2020;14:1609-20. [PMID: 32425506 DOI: 10.2147/DDDT.S243383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yokoda RT, Nagalo BM, Borad MJ. Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines. 2018;6. [PMID: 29534501 DOI: 10.3390/biomedicines6010033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zheng RP, Ma DK, Li Z, Zhang HF. MiR-145 Regulates the Chemoresistance of Hepatic Carcinoma Cells Against 5-Fluorouracil by Targeting Toll-Like Receptor 4. Cancer Manag Res 2020;12:6165-75. [PMID: 32801865 DOI: 10.2147/CMAR.S257598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol 2022. [PMID: 35258675 DOI: 10.1007/s00330-022-08643-4] [Reference Citation Analysis]
6 Raeisi F, Abolfathi M, Ahmadi-naji R, Iranparast S, Noshadi E, Akbari A, Mahmoudi E, Khaledi M, Arshi A. ARA lncRNA, is upregulated in liver and breast tumor tissues. Mol Biol Rep 2019;46:77-82. [DOI: 10.1007/s11033-018-4447-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Dang S, Zhou J, Wang Z, Wang K, Dai S, He S. MiR-299-3p functions as a tumor suppressor via targeting Sirtuin 5 in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2018;106:966-75. [DOI: 10.1016/j.biopha.2018.06.042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
8 Wege H, Schulze K, von Felden J, Calderaro J, Reig M; rare liver tumors working group of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. Eur J Med Genet 2021;64:104313. [PMID: 34418585 DOI: 10.1016/j.ejmg.2021.104313] [Reference Citation Analysis]
9 Abdalla Y, Abdalla A, Hamza AA, Amin A. Safranal Prevents Liver Cancer Through Inhibiting Oxidative Stress and Alleviating Inflammation. Front Pharmacol 2021;12:777500. [PMID: 35177980 DOI: 10.3389/fphar.2021.777500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Braeuning A, Schwarz M. Regulation of expression of drug-metabolizing enzymes by oncogenic signaling pathways in liver tumors: a review. Acta Pharm Sin B 2020;10:113-22. [PMID: 31993310 DOI: 10.1016/j.apsb.2019.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Madakashira BP, Zhang C, Macchi F, Magnani E, Sadler KC. Nuclear Organization during Hepatogenesis in Zebrafish Requires Uhrf1. Genes (Basel) 2021;12:1081. [PMID: 34356097 DOI: 10.3390/genes12071081] [Reference Citation Analysis]
12 Duan F, Wang YY, Xu DG, Shi J, Chen LY, Cui L, Bai YH, Xu Y, Yuan J, Chang C. Feasibility of terahertz imaging for discrimination of human hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(2): 153-160 [PMID: 30788041 DOI: 10.4251/wjgo.v11.i2.153] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
13 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
14 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]